血栓素B2

血栓素B2，Thromboxane B2，TXA2 的一种非活性代谢产物。更多视频请关注视频号【艾维缔】。哔哩哔哩【IVDSHOW】。抖音【军哥聊表观】。

关键词

血栓素B2

所属分类

小分子

目录号

19030

获取报价

产品组分

内容	型号	规格	储存温度
血栓素B2	19030-01	1mg	-20°C
血栓素B2	19030-02	5mg	-20°C
血栓素B2	19030-03	10mg	-20°C
操作手册	1	1	常温

文件资源

文件下载 文件内容 资源说明

19030-血栓素B2 操作手册

19030-血栓素B2相关说明宣传单页
营销中心
注意事项

保存建议厂家推荐蓝冰运输。当您收到产品后，按照说明书建议保存于-20°C。
FAQ
Product Description References

1. Needleman, P., Moncada, S., Bunting, S., et al. Identification of an enzyme in platelet microsomes which generates thromboxane A₂ from prostaglandin endoperoxides. Nature 261(5561), 558-560 (1976).

2. Patrono, C., Ciabattoni, G., Pugliese, F., et al. Estimated rate of thromboxane secretion into the circulation of normal humans. J. Clin. Invest. 77(2), 590-594 (1986).

3. Uyama, O., Matsumoto, M., Fujisawa, A., et al. Plasma concentrations of thromboxane B₂ in patients with hypertension or cerebrovascular disease. Prostaglandins Med. 7(3), 199-207 (1981).

4. Arantes, F.B.B., Menezes, F.R., Franci, A., et al. Influence of direct thrombin inhibitor and low molecular weight heparin on platelet function in patients with coronary artery disease: A prospective interventional trial. Adv. Ther. 37(1), 420-430 (2020).

5. Ferroni, P., Riondino, S., Vazzana, N., et al. Biomarkers of platelet activation in acute coronary syndromes. Thromb. Haemost. 108(6), 1109-1123 (2012).

6. Patrono, C., Ciabattoni, G., Patrignani, P., et al. Evidence for a renal origin of urinary thromboxane B₂ in health and disease. Adv. Prostaglandin Thromboxane Leukot. Res. 11, 493-498 (1983).

7. Lawson, J.A., Patrono, C., Ciabattoni, G., et al. Long-lived enzymatic metabolites of thromboxane B₂ in the human circulation. Anal. Biochem. 155(1), 198-205 (1986).

Product Citations

Pang, Y., Liu, X., Zhao, C., et al. LC-MS/MS-based arachidonic acid metabolomics in acute spinal cord injury reveals the upregulation of 5-LOX and COX-2 products. Free Radic. Biol. Med. 193(Pt 1), 363-372 (2022).

Archambault, A.-S., Zaid, Y., Rakotoarivelo, V., et al. High levels of eicosanoids and docosanoids in the lungs of intubated COVID-19 patients. FASEB J. 35(6), e21666 (2021).

Roberts, L.M., Schwarz, B., Speranza, E., et al. Pulmonary infection induces persistent, pathogen-specific lipidomic changes influencing trained immunity. iScience 24(9), 103025 (2021).

Archambault, A.-S., Zaid, Y., Rakotoarivelo, V., et al. Lipid storm within the lungs of severe COVID-19 patients: Extensive levels of cyclooxygenase and lipoxygenase-derived inflammatory metabolites. medRxiv (2020).

Meriwether, D., Sulaiman, D., Volpe, C., et al. Apolipoprotein A-I mimetics mitigate intestinal inflammation in COX2-dependent inflammatory bowel disease model. J. Clin. Invest. 130, 3670-3685 (2019).

Dalli, J., Colas, R.A., Walker, M.E., et al. Lipid Mediator Metabolomics via LC-MS/MS Profiling and Analysis. Clinical Metabolomics 59-72 (2018).

Sorgi, C.A., Peti, A.P.F., Petta, T., et al. Comprehensive high-resolution multiple-reaction monitoring mass spectrometry for targeted eicosanoid assays. Sci. Data 5, 180167 (2018).

Gouveia-Figueira, S., Karlsson, J., Deplano, A., et al. Characterisation of (R)-2-(2-fluorobiphenyl-4-yl)-N-(3-methylpyridin-2-yl)propanamide as a dual fatty acid amide hydrolase: Cyclooxygenase inhibitor. PLoS One 10(9), e0139212 (2015).